Cargando…

Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients

To determine whether in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue lymphoma (MALT), delayed–time-point 2-(18)F-fluoro-2-deoxy-d-glucose-positron emission tomography ((18)F-FDG-PET) performs better than standard–time-point (18)F-FDG-PET. MATERIALS...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayerhoefer, Marius E., Giraudo, Chiara, Senn, Daniela, Hartenbach, Markus, Weber, Michael, Rausch, Ivo, Kiesewetter, Barbara, Herold, Christian J., Hacker, Marcus, Pones, Matthias, Simonitsch-Klupp, Ingrid, Müllauer, Leonhard, Dolak, Werner, Lukas, Julius, Raderer, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703065/
https://www.ncbi.nlm.nih.gov/pubmed/26402137
http://dx.doi.org/10.1097/RLU.0000000000001005
_version_ 1782408690665521152
author Mayerhoefer, Marius E.
Giraudo, Chiara
Senn, Daniela
Hartenbach, Markus
Weber, Michael
Rausch, Ivo
Kiesewetter, Barbara
Herold, Christian J.
Hacker, Marcus
Pones, Matthias
Simonitsch-Klupp, Ingrid
Müllauer, Leonhard
Dolak, Werner
Lukas, Julius
Raderer, Markus
author_facet Mayerhoefer, Marius E.
Giraudo, Chiara
Senn, Daniela
Hartenbach, Markus
Weber, Michael
Rausch, Ivo
Kiesewetter, Barbara
Herold, Christian J.
Hacker, Marcus
Pones, Matthias
Simonitsch-Klupp, Ingrid
Müllauer, Leonhard
Dolak, Werner
Lukas, Julius
Raderer, Markus
author_sort Mayerhoefer, Marius E.
collection PubMed
description To determine whether in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue lymphoma (MALT), delayed–time-point 2-(18)F-fluoro-2-deoxy-d-glucose-positron emission tomography ((18)F-FDG-PET) performs better than standard–time-point (18)F-FDG-PET. MATERIALS AND METHODS: Patients with untreated histologically verified MALT lymphoma, who were undergoing pretherapeutic (18)F-FDG-PET/computed tomography (CT) and consecutive (18)F-FDG-PET/magnetic resonance imaging (MRI), using a single (18)F-FDG injection, in the course of a larger-scale prospective trial, were included. Region-based sensitivity and specificity, and patient-based sensitivity of the respective (18)F-FDG-PET scans at time points 1 (45–60 minutes after tracer injection, TP1) and 2 (100–150 minutes after tracer injection, TP2), relative to the reference standard, were calculated. Lesion-to-liver and lesion-to-blood SUV(max) (maximum standardized uptake values) ratios were also assessed. RESULTS: (18)F-FDG-PET at TP1 was true positive in 15 o f 23 involved regions, and (18)F-FDG-PET at TP2 was true-positive in 20 of 23 involved regions; no false-positive regions were noted. Accordingly, region-based sensitivities and specificities were 65.2% (confidence interval [CI], 45.73%–84.67%) and 100% (CI, 100%-100%) for (18)F-FDG-PET at TP1; and 87.0% (CI, 73.26%–100%) and 100% (CI, 100%-100%) for (18)F-FDG-PET at TP2, respectively. FDG-PET at TP1 detected lymphoma in at least one nodal or extranodal region in 7 of 13 patients, and (18)F-FDG-PET at TP2 in 10 of 13 patients; accordingly, patient-based sensitivity was 53.8% (CI, 26.7%–80.9%) for (18)F-FDG-PET at TP1, and 76.9% (CI, 54.0%–99.8%) for (18)F-FDG-PET at TP2. Lesion-to-liver and lesion-to-blood maximum standardized uptake value ratios were significantly lower at TP1 (ratios, 1.05 ± 0.40 and 1.52 ± 0.62) than at TP2 (ratios, 1.67 ± 0.74 and 2.56 ± 1.10; P = 0.003 and P = 0.001). CONCLUSIONS: Delayed–time-point imaging may improve (18)F-FDG-PET in MALT lymphoma.
format Online
Article
Text
id pubmed-4703065
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-47030652016-01-19 Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients Mayerhoefer, Marius E. Giraudo, Chiara Senn, Daniela Hartenbach, Markus Weber, Michael Rausch, Ivo Kiesewetter, Barbara Herold, Christian J. Hacker, Marcus Pones, Matthias Simonitsch-Klupp, Ingrid Müllauer, Leonhard Dolak, Werner Lukas, Julius Raderer, Markus Clin Nucl Med Original Articles To determine whether in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue lymphoma (MALT), delayed–time-point 2-(18)F-fluoro-2-deoxy-d-glucose-positron emission tomography ((18)F-FDG-PET) performs better than standard–time-point (18)F-FDG-PET. MATERIALS AND METHODS: Patients with untreated histologically verified MALT lymphoma, who were undergoing pretherapeutic (18)F-FDG-PET/computed tomography (CT) and consecutive (18)F-FDG-PET/magnetic resonance imaging (MRI), using a single (18)F-FDG injection, in the course of a larger-scale prospective trial, were included. Region-based sensitivity and specificity, and patient-based sensitivity of the respective (18)F-FDG-PET scans at time points 1 (45–60 minutes after tracer injection, TP1) and 2 (100–150 minutes after tracer injection, TP2), relative to the reference standard, were calculated. Lesion-to-liver and lesion-to-blood SUV(max) (maximum standardized uptake values) ratios were also assessed. RESULTS: (18)F-FDG-PET at TP1 was true positive in 15 o f 23 involved regions, and (18)F-FDG-PET at TP2 was true-positive in 20 of 23 involved regions; no false-positive regions were noted. Accordingly, region-based sensitivities and specificities were 65.2% (confidence interval [CI], 45.73%–84.67%) and 100% (CI, 100%-100%) for (18)F-FDG-PET at TP1; and 87.0% (CI, 73.26%–100%) and 100% (CI, 100%-100%) for (18)F-FDG-PET at TP2, respectively. FDG-PET at TP1 detected lymphoma in at least one nodal or extranodal region in 7 of 13 patients, and (18)F-FDG-PET at TP2 in 10 of 13 patients; accordingly, patient-based sensitivity was 53.8% (CI, 26.7%–80.9%) for (18)F-FDG-PET at TP1, and 76.9% (CI, 54.0%–99.8%) for (18)F-FDG-PET at TP2. Lesion-to-liver and lesion-to-blood maximum standardized uptake value ratios were significantly lower at TP1 (ratios, 1.05 ± 0.40 and 1.52 ± 0.62) than at TP2 (ratios, 1.67 ± 0.74 and 2.56 ± 1.10; P = 0.003 and P = 0.001). CONCLUSIONS: Delayed–time-point imaging may improve (18)F-FDG-PET in MALT lymphoma. Lippincott Williams & Wilkins 2016-02 2016-01-18 /pmc/articles/PMC4703065/ /pubmed/26402137 http://dx.doi.org/10.1097/RLU.0000000000001005 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Original Articles
Mayerhoefer, Marius E.
Giraudo, Chiara
Senn, Daniela
Hartenbach, Markus
Weber, Michael
Rausch, Ivo
Kiesewetter, Barbara
Herold, Christian J.
Hacker, Marcus
Pones, Matthias
Simonitsch-Klupp, Ingrid
Müllauer, Leonhard
Dolak, Werner
Lukas, Julius
Raderer, Markus
Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients
title Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients
title_full Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients
title_fullStr Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients
title_full_unstemmed Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients
title_short Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients
title_sort does delayed-time-point imaging improve 18f-fdg-pet in patients with malt lymphoma?: observations in a series of 13 patients
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703065/
https://www.ncbi.nlm.nih.gov/pubmed/26402137
http://dx.doi.org/10.1097/RLU.0000000000001005
work_keys_str_mv AT mayerhoefermariuse doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients
AT giraudochiara doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients
AT senndaniela doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients
AT hartenbachmarkus doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients
AT webermichael doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients
AT rauschivo doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients
AT kiesewetterbarbara doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients
AT heroldchristianj doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients
AT hackermarcus doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients
AT ponesmatthias doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients
AT simonitschkluppingrid doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients
AT mullauerleonhard doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients
AT dolakwerner doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients
AT lukasjulius doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients
AT raderermarkus doesdelayedtimepointimagingimprove18ffdgpetinpatientswithmaltlymphomaobservationsinaseriesof13patients